Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials

[1]  J. Ciolino,et al.  Alcaftadine 0.25% Versus Olopatadine 0.2% In Prevention Of Ocular Itching In Allergic Conjunctivitis , 2014 .

[2]  J. Ciolino,et al.  A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model , 2013, Journal of asthma and allergy.

[3]  P. Demoly,et al.  Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface , 2012, Allergy.

[4]  F. Paulsen,et al.  Structural and Functional Alteration of Corneal Epithelial Barrier Under Inflammatory Conditions , 2012, Current eye research.

[5]  L. Bielory,et al.  Ophthalmic antihistamines and H1–H4 receptors , 2012, Current opinion in allergy and clinical immunology.

[6]  R. Namdar,et al.  Alcaftadine: a topical antihistamine for use in allergic conjunctivitis. , 2011, Drugs of today.

[7]  N. Rosário,et al.  Epidemiology of allergic conjunctivitis. , 2011, Current opinion in allergy and clinical immunology.

[8]  G. Torkildsen,et al.  The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis , 2011, Current medical research and opinion.

[9]  K. Lane,et al.  Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis , 2011, Drug design, development and therapy.

[10]  J. Greiner,et al.  Clinical Ophthalmology Dovepress Evaluation of Alcaftadine 0.25% Ophthalmic Solution in Acute Allergic Conjunctivitis at 15 Minutes and 16 Hours after Instillation versus Placebo and Olopatadine 0.1% , 2022 .

[11]  L. Bielory,et al.  The epidemiology of ocular and nasal allergy in the United States, 1988-1994. , 2010, The Journal of allergy and clinical immunology.

[12]  M. Abelson,et al.  Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. , 2009, Clinical therapeutics.

[13]  C. Kamei,et al.  Role of histamine H(4) receptor in allergic conjunctivitis in mice. , 2009, European journal of pharmacology.

[14]  R. Thurmond,et al.  The histamine H4 receptor antagonist JNJ7777120 induces increases in the histamine content of the rat conjunctiva , 2009, Inflammation Research.

[15]  D. Strachan,et al.  Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in Childhood , 2008, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[16]  R. D. Gross,et al.  Perception and quality of life associated with the use of olopatadine 0.2% (Pataday™) in patients with active allergic conjunctivitis , 2007, Advances in therapy.

[17]  C. de Dominicis,et al.  Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities , 2007, Current opinion in allergy and clinical immunology.

[18]  M. Blaiss.  Allergic rhinoconjunctivitis: burden of disease. , 2007, Allergy and asthma proceedings.

[19]  M. Abelson,et al.  Efficacy of Once-Daily Olopatadine 0.2% Ophthalmic Solution Compared to Twice-Daily Olopatadine 0.1% Ophthalmic Solution for the Treatment of Ocular Itching Induced by Conjunctival Allergen Challenge , 2007, Current eye research.

[20]  C. Creuzot-Garcher,et al.  Le test de provocation conjonctival : recommandations pratiques pour le diagnostic des conjonctivites allergiques , 2006 .

[21]  P. Demoly,et al.  [Conjunctival provocation test: recommendations]. , 2006, Journal francais d'ophtalmologie.

[22]  L. Bielory.  Allergic diseases of the eye. , 2006, The Medical clinics of North America.

[23]  L. Bielory,et al.  Histamine receptors and the conjunctiva , 2005, Current opinion in allergy and clinical immunology.

[24]  Santa Jeremy Ono,et al.  Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. , 2005, The Journal of allergy and clinical immunology.

[25]  R. Thurmond,et al.  Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation , 2004, British journal of pharmacology.

[26]  S. Whitcup,et al.  Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. , 2004, Clinical therapeutics.

[27]  M. Abelson,et al.  Conjunctival allergen challenge: Models in the investigation of ocular allergy , 2003, Current allergy and asthma reports.

[28]  M. Abelson.  Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[29]  W. Chambers,et al.  Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. , 1990, Archives of ophthalmology.

[30]  M. Abelson,et al.  H2-receptors in the human ocular surface. , 1981, Archives of ophthalmology.